Medios AG acquires majority stake in Caesar & Loretz (Caelo)
What's the deal? Medios AGDealroom has a profile for this one. Try Dealroom → signed an agreement on August 11, 2026 to acquire 74% of Caesar & Loretz GmbHDealroom has a profile for this one. Try Dealroom → (Caelo), a Hilden-based supplier of active pharmaceutical ingredients (APIs), excipients, and raw materials. Caelo serves pharmacies, hospitals, and industrial customers in Germany and expects revenue of about €40 million for fiscal 2026.
What are the terms? The debt-financed purchase price sits in the upper single-digit million-euro range and depends on Caelo's future performance. Put and call options cover the remaining 26% of shares, and Caelo will be fully consolidated once the deal completes.
Why now? The transaction marks Medios' entry into the German market for active pharmaceutical ingredients and excipients. It also lays the foundation for what the company calls a European platform for Compounding Essentials.
What's next? Closing hinges on customary conditions and is expected in the fourth quarter of 2026. The acquisition has no impact on Medios' consolidated forecast for fiscal 2026, which it updated on July 28, 2026.
The signal: The deal reflects consolidation in Europe's specialty pharma supply chain, as listed players build cross-border platforms around individualised and compounded medicines rather than finished-drug distribution alone.
Read more: Ad-hoc-news.de
Image credit: zhouxuan12345678
